Kobayashi Pharmaceutical Co (4967) AI Stock Analysis

• Market Cap: ¥396.62B
• Dividend Yield: 1.93%
• Average Volume (3M): 252.09K
• Price to Earnings (P/E): 37.1
• Beta (1Y): 0.31
• Revenue Growth: -8.36%
• EPS Growth: -38.35%
• Country: JP
• Employees: 3,615
• Sector: Healthcare
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 21.86
• Shares Outstanding: 78,050,000
• 10 Day Avg. Volume: 145,180
• 30 Day Avg. Volume: 252,086
• PEG Ratio: 5.62
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,100.74
• Price Target Upside: -4.62% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 61 Neutral
• Price Target: ¥5,606.00 ▲(4.82%Upside)

Kobayashi Pharmaceutical's strong balance sheet and low leverage are positive, but the negative revenue growth and profitability pressures weigh on the financial performance. Technical indicators are neutral, and the stock's valuation suggests it may be overvalued, resulting in a moderate overall stock score.

Kobayashi Pharmaceutical Co Business Overview & Revenue Model

Company Description

Kobayashi Pharmaceutical Co., Ltd. is a Japanese company that operates primarily in the pharmaceutical industry. It engages in the development, manufacture, and sale of consumer healthcare products, including over-the-counter (OTC) medications, household goods, and personal care products. The company's wide range of products includes remedies for common ailments, health supplements, and sanitary goods. With a focus on innovation and quality, Kobayashi Pharmaceutical aims to improve the health and wellness of its customers.

How the Company Makes Money

Kobayashi Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its over-the-counter (OTC) medications, household products, and personal care goods. The company markets a diverse portfolio of products that target everyday health and hygiene needs, such as cold remedies, pain relief medications, and skin care solutions. It also engages in the development and sale of health supplements. The company's revenue model is driven by its strong distribution network, brand recognition, and its ability to consistently launch innovative products that meet consumer demands. Additionally, strategic partnerships and collaborations may also play a role in expanding its market reach and enhancing its product offerings.

Kobayashi Pharmaceutical Co Financial Statement Overview

Summary

Kobayashi Pharmaceutical demonstrates a solid financial position with strong equity and low debt levels. However, challenges exist in revenue growth and profitability, with a declining net profit margin and negative free cash flow needing attention to sustain long-term financial health.

Income Statement

Kobayashi Pharmaceutical has demonstrated stable revenue generation with a moderate gross profit margin of around 53% for 2024. However, there is a notable decline in net profit margin from 11.7% in 2023 to 6.1% in 2024, indicating pressure on profitability. The revenue growth rate was negative at -4.53% from 2023 to 2024, signaling a contraction. EBIT and EBITDA margins are reasonably healthy but show slight declines, reflecting increased operational challenges.

Balance Sheet

The company maintains a strong balance sheet with a very low debt-to-equity ratio of 0.004, reflecting minimal leverage risk. The equity ratio remains robust at approximately 80.4%, indicating strong financial stability and shareholder equity. Return on equity (ROE) has decreased to 4.7% in 2024, reflecting reduced net income relative to equity.

Cash Flow

Free cash flow has turned negative in 2024, a significant drop from the positive free cash flow of 4.79 billion yen in 2023, signaling cash flow challenges. The operating cash flow to net income ratio remains positive, indicating that operating activities are still generating sufficient cash relative to net income, but free cash flow to net income ratio is negative, highlighting concerns over capital expenditures.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	165.60B	173.46B	166.26B	155.25B	150.51B
Gross Profit	87.60B	96.38B	92.33B	88.77B	85.27B
EBITDA	32.73B	33.65B	31.86B	30.79B	29.91B
Net Income	10.07B	20.34B	20.02B	19.71B	19.20B
Balance Sheet
Total Assets	265.37B	267.47B	255.83B	252.55B	238.37B
Cash, Cash Equivalents and Short-Term Investments	65.75B	79.84B	104.53B	109.05B	94.34B
Total Debt	846.00M	987.00M	792.00M	630.00M	688.00M
Total Liabilities	51.90B	62.66B	57.93B	56.95B	55.78B
Stockholders Equity	213.47B	204.82B	197.90B	195.60B	182.58B
Cash Flow
Free Cash Flow	-14.81B	4.79B	15.69B	18.23B	19.84B
Operating Cash Flow	11.25B	18.36B	31.91B	22.42B	23.99B
Investing Cash Flow	-18.41B	-19.58B	-14.31B	7.99B	-12.66B
Financing Cash Flow	-7.77B	-19.46B	-20.76B	-10.38B	-6.02B

Kobayashi Pharmaceutical Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5348.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4967, the sentiment is Positive. The current price of 5348 is above the 20-day moving average (MA) of 5258.60, above the 50-day MA of 5295.63, and below the 200-day MA of 5530.68, indicating a neutral trend. The MACD of -16.66 indicates Negative momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 93.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4967.

Kobayashi Pharmaceutical Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4527	76 Outperform	¥492.18B	15.58	12.05%	1.70%	13.95%	0.37%
8283	73 Outperform	¥265.93B	11.65	7.98%	2.46%	3.14%	11.57%
4927	69 Neutral	$282.84B	37.87	4.49%	4.07%	-0.74%	-25.66%
Sector *	65 Neutral	¥355.15B	11.37	-2.99%	2.48%	11.78%	-10.17%
4922	63 Neutral	$330.49B	56.42	2.08%	2.42%	4.63%	-60.17%
4967	61 Neutral	¥396.62B	37.10	5.17%	1.93%	-8.36%	-38.35%
4912	59 Neutral	$397.87B	18.69	7.58%	1.98%	2.30%	33.87%